Benzinga | Oct 15, 2020 05:47AM EDT

NantKwest Announces FDA Authorizes Phase 1 Trial of ImmunityBio's Novel COVID-19 Vaccine Candidate hAd5; Dual Construct is Designed to Drive Both T Cell and Antibody Immunity

https://nantkwest.com/fda-authorizes-phase-1-trial-of-immunitybios-novel-covid-19-vaccine-candidate-had5-dual-construct-is-designed-to-drive-both-t-cell-and-antibody-immunity/